The characteristics of the ideal drug to be monitored by serum or blood concentration are listed in Table 2 . Digoxin, an excellent example of such a drug, is a cardiac glycoside, the major action of which is to increase the force of contraction of the heart, and digitalis has been in use for >200 years for the treatment of congestive heart failure, a use 
The characteristics of the ideal drug to be monitored by serum or blood concentration are listed in Table 2 . Digoxin, an excellent example of such a drug, is a cardiac glycoside, the major action of which is to increase the force of contraction of the heart, and digitalis has been in use for >200 years for the treatment of congestive heart failure, a use that William Withering astutely observed in 1775 [1] . The difficulty in relating the HMG-C0A, 3-tydroxy-3-methylgIutaryI-coenzyme A appropriate dose of digitalis to effect was illustrated by his initial recommendations, which were to "continue the medicine until the urine flows, or sickness or purging take place." Withering further observed that in some patients the "pulse would be retarded to an alarming degree, without any other preceding effect." Therefore, he altered his recommendation for the use of digitalis to "let it be continued until it either acts on the kidneys, the stomach, the pulse or the bowels; let it be stopped upon the appearance of any one of these effects" [3] reported that patients with congestive heart failure who were treated with digoxin and who had serum concentrations of 0.9-1.2 j.tg/L could exercise substantially longer than patients who were given placebo. However, there was no increase in exercise duration in patients who were treated with digoxin and who had concentra-
Other characteristics that make digoxin an ideal drug to monitor by serum drug concentration are that it has few active metabolites and most of the drug is present in unchanged form. In addition, many drugs interact with digoxin; most raise serum digoxin concentrations, frequently to the toxic range with potentially dangerous or fatal consequences [4] . For example, medications such as quinidine that are usually prescribed for the treatment of tachyarrhythmias raise serum digoxin concentrations. The digoxinlquinidine interaction can be particularly hazardous, and fatalities have been reported with this combination, particularly before this hazardous drug interaction was known.
Finally, common alterations in the pharmacokinetics of digoxin are not readily assessed. For example, renal function decreases gradually with age. After age 65 years, there may be a 50% decrease in creatinine clearance; this is in turn reflected by a decrease in digoxin clearance. Because muscle mass decreases with aging and less creatinine is released from muscle, the serum creatinine may not reflect the decrease in renal function [5] .
Because digoxin concentrations are used to titrate digoxin, blood should be drawn for assay after an interval that allows distribution of the drug within the body. The best time to obtain a serum concentration is 6-12 h after the drug is given orally and >4 h after the last intravenous dose [6] . In interpreting These clots can become dislodged and cause strokes. Before treatment with warfann of patients with atrial fibrillation, this arrhythmia was a major cause of stroke. Several trials involving thousands of patients with atrial fibrillation have been conducted to answer the question of the optimal dose and effect of warfarin measured by the prothrombin time. The aim is to provide the greatest protection against stroke with the lowest rate of severe bleeding complications, which are defined as bleeding that requires hospitalization or causes a cerebral hemorrhage. This dose has now been established as an INIR of 2-3 /7]. However, the question of whether all patients with atrial fibrillation should be treated with warfarin is still unresolved. The annual risk of bleeding is 1.7% in patients with atnial fibrillation who are treated with warfarin; in atrial fibrillation patients who are at low risk, the annual stroke rate is 1% (A low-risk patient is defined as younger than 65, with no diabetes, high blood pressure, or a history of embolic stroke. Therefore, the use of warfarin in this low-risk group may not be warranted. In patients age 75 years who have at least one of the abovementioned risk factors, the annual stroke rate is 8.1%; however, the risk of severe bleeding also is increased. Therefore, studies to determine the optimal 1NR and (or) combination of antithrombotic agents are continuing. this may require discontinuation of the drug or a decrease in dose. If a drug lowers blood pressure but causes adverse side effects, it may be necessary to decrease the dose. The desired effect may persist, but the adverse effects can diminish or become tolerable. For example, decreasing the dose of beta blockers may ameliorate or eliminate fatigue, lethargy, and impotence. Cardiovascular drugs such as verapamil, diltiazem, and beta blockers may be used to decrease the rate response of the ventricle to the rapid rate of the atrium in patients who have atrial fibrillation.
Again, one can assess this effect clinically by measuring the pulse. Although the major goal of therapy may be to decrease the rate, the therapeutic end point may not be achieved because of the other actions of the drug, such as bradycardia and hypotension. The response to diuretics in patients with congestive heart failure is readily assessed by the increase in urine output, or it may be determined by a rapid decrease in weight over hours or days that reflects diuretic-produced fluid loss. These findings are usually reflected by a decrease in the signs and symptoms of heart failure. Coronary vasodilators such as nitroglycerin immediately relieve angina pectonis, which is due to a discrepancy between myocardial oxygen demand caused by excitement or exercise and the inability of the coronary circulation to satisfy that demand. For some cardiovascular drugs, a broad range of serum concentrations is associated with therapeutic or adverse effects. In addition, active metabolites may not be routinely measured, or, if assayed, their therapeutic roles may be unclear. An example of the wide range of therapeutic serum concentrations associated with a therapeutic effect was given in a study by Giardina et al. [13] . Thirty-three patients with heart disease who had >10 premature ventricular beats per hour were treated with 3 g of procainamide per day. The dose was increased daily by 1.5 g until the daily dose was 7.5 g. Twenty-two patients had arrhythmia suppression (defined as >75% decrease in premature ventricular beat frequency). Serum procainamide concentrations associated with the therapeutic effect were 1.8-17.0 mg/L. In the patients who were effectively treated, the serum concentration of the major metabolite, N-acetylprocainamide, had a similar wide range of 1.8-25.2 mgfL.
The attainment of "therapeutic" serum procainamide concentrations does not ensure clinically effective arrhythmia suppression. In another study, Waxman et al. administered procainamide to 126 patients who had sustained ventricular arrhythmias induced by inserting a catheter into the right ventricle and stimulating the heart. Most patients received the drug intravenously at a dose of 1-2.5 g followed by a constant infusion. The efficacy of the drug was assessed by the inability to stimulate the abnormal rhythm electrically in these patients after procainamide was administered.
The serum concentrations of procainamide were 13.8 ± 6 mg/L in the patients who were still inducible and 12. 
